Skip to main content

Dutrebis and Alcohol/Food Interactions

There is 1 alcohol/food/lifestyle interaction with Dutrebis (lamivudine / raltegravir).

Major

Lamivudine High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)

Major Potential Hazard, Moderate plausibility

NRTIs - pancreatitis

The nucleoside reverse transcriptase inhibitors, didanosine, stavudine, and lamivudine, may cause pancreatitis. The incidence is generally low but is up to 7% with didanosine, and up to 18% in pediatric patients given lamivudine. Patients with a history of or known risk factors for pancreatitis (such as alcohol abuse or hypertriglyceridemia) should be monitored closely during therapy with these agents. Therapy should be discontinued at the first signs/symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.

References (3)
  1. (2019) "Product Information. Epivir (lamiVUDine)." ViiV Healthcare, SUPPL-39
  2. (2018) "Product Information. Videx (didanosine)." Bristol-Myers Squibb, SUPPL-54
  3. (2018) "Product Information. Zerit (stavudine)." Bristol-Myers Squibb, SUPPL-41

Switch to consumer interaction data

Dutrebis drug interactions

There are 115 drug interactions with Dutrebis (lamivudine / raltegravir).

Dutrebis disease interactions

There are 8 disease interactions with Dutrebis (lamivudine / raltegravir) which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer